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Background: Matrix metalloproteinases can promote invasion and metastasis, which are very frequent in renal cell
carcinoma even at the time of diagnosis. Knowing the reversion-inducing cysteine-rich protein with Kazal motifs
(RECK) as an inhibitor of matrix metalloproteinases and the extracellular matrix metalloproteinase inducer
(EMMPRIN) protein as inducer, we aimed to determine their expression, localization and possible antagonistic action
in the pathogenesis and progression of renal cell tumors in a retrospective study.
Methods: Tumor and adjacent normal tissues of 395 nephrectomized patients were immunostained for RECK and
EMMPRIN on a tissue microarray.
Results: RECK strongly decreased in renal cell carcinoma compared to normal counterparts (Wilcoxon signed rank
test, P < 0.001), and it discriminated tumor entities showing the highest expression in oncocytomas. EMMPRIN,
however, could be significantly correlated to pT stage and Fuhrman grading (Spearman’s correlation coefficient
rs = 0.289 and rs = 0.382, respectively). Higher expression of EMMPRIN was associated with decreased overall survival
in Kaplan-Meier analysis (P < 0.001), and the EMMPRIN level could independently predict survival for cases without
metastasis and involvement of lymph nodes. Decreased RECK expression was confirmed by Western blotting in
tissue of eight normal/tumor matches of patients after radical nephrectomy, whereas the EMMPRIN pattern
appeared to be heterogeneous.
Conclusions: We propose RECK down regulation in renal cell carcinoma to be an early event that facilitates tumor
formation and progression. EMMPRIN, however, as a prognostic tumor marker, increases only when aggressiveness
is proceeding and could add an additional step to invasive properties of renal cell carcinoma.
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Kidney cancer is not the most common malignancy, but
with a five-year survival rate of 70% in the United States
[1] the outcome is often poor. In renal cell carcinoma
(RCC) which represent the majority of 85-90% of kidney
neoplasms [2,3], survival is mostly determined by distal
metastases detected in 30% of the patients even at the* Correspondence: anja.rabien@charite.de
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reproduction in any medium, provided the ortime of diagnosis [2]. Usually, RCC can be recognized by
sonography, but as symptoms are lacking until late stages
of the disease, metastasis of RCC is the main problem in
therapeutic approaches [2,3]. Due to the resistance of RCC
to radio- and chemotherapy, only surgery can be curative if
RCC is diagnosed at an early stage [2,3]. Current so-called
“targeted therapies” using tyrosine kinase inhibitors, mTOR
inhibitors or antiangiogenic antibodies alone or in combi-
nations are able to slightly extend progression-free survival
[2,3], but further therapeutic improvements are needed.
Decisions for treatment are based on tumor stage and theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 RECK and EMMPRIN staining in renal cell tumors related to clinicopathological parameters
Variable Cases (n / %) RECK expression (number of cases / %) P value*
0 1 2 3
Age ≤60 years 197 (49.9) 161 (81.7) 27 (13.7) 8 (4.1) 1 (0.5) 0.580
>60 years 198 (50.1) 164 (82.8) 22 (11.1) 5 (2.5) 7 (3.5)
Sex male 264 (66.8) 212 (80.3) 36 (13.6) 11 (4.2) 5 (1.9) 0.234
female 131 (33.2) 113 (86.3) 13 (9.9) 2 (1.5) 3 (2.3)
pT status pT1-2 265 (67.1) 216 (81.5) 32 (12.1) 10 (3.8) 7 (2.6) 0.250
pT3-4 130 (32.9) 109 (83.8) 17 (13.1) 3 (2.3) 1 (0.8)
Fuhrman grade 1-2 348 (88.1) 285 (81.9) 43 (12.4) 12 (3.4) 8 (2.3) 0.338
3-4 47 (11.9) 40 (85.1) 6 (12.8) 1 (2.1) 0 (0.0)
Nodal status** pN0 214 (89.9) 182 (85.0) 25 (11.7) 5 (2.3) 2 (0.9) 0.878
pN+ 24 (10.1) 20 (83.3) 3 (12.5) 1 (4.2) 0 (0.0)
Metastases*** M0 338 (90.6) 278 (82.2) 41 (12.1) 12 (3.6) 7 (2.1) 0.300
M1 35 (9.4) 31 (88.6) 3 (8.6) 1 (2.9) 0 (0.0)
Margin status**** R0 357 (94.4) 291 (81.5) 46 (12.9) 12 (3.4) 8 (2.2) 0.603
R+ 21 (5.6) 18 (85.7) 2 (9.5) 1 (4.8) 0 (0.0)
Tumor subtype
Clear cell RCC 322 (81.5) 291 (90.4) 27 (8.4) 3 (0.9) 1 (0.3) <0.001
Papillary RCC 43 (10.9) 23 (53.5) 11 (25.6) 8 (18.6) 1 (2.3)
Chromophobe RCC 22 (5.6) 10 (45.5) 7 (31.8) 1 (4.5) 4 (18.2)
Oncocytoma 8 (2.0) 1 (12.5) 4 (50.0) 1 (12.5) 2 (25.0)
EMMPRIN expression (number of cases / %)
0 1 2 3
Age ≤60 years 196 (49.7) 7 (3.6) 57 (29.1) 70 (35.7) 62 (31.6) 0.479
>60 years 198 (50.3) 8 (4.0) 54 (27.3) 87 (43.9) 49 (24.7)
Sex male 263 (66.8) 13 (4.9) 70 (26.6) 102 (38.8) 78 (29.7) 0.797
Female 131 (33.2) 2 (1.5) 41 (31.3) 55 (42.0) 33 (25.2)
pT status pT1-2 265 (67.3) 14 (5.3) 86 (32.5) 112 (42.3) 53 (20.0) <0.001
pT3-4 129 (32.7) 1 (0.8) 25 (19.4) 45 (34.9) 58 (45.0)
Fuhrman grade 1-2 347 (88.1) 15 (4.3) 109 (31.4) 141 (40.6) 82 (23.6) <0.001
3-4 47 (11.9) 0 (0.0) 2 (4.3) 16 (34.0) 29 (61.7)
Nodal status** pN0 213 (89.9) 6 (2.8) 63 (29.6) 78 (36.6) 66 (31.0) 0.003
pN+ 24 (10.1) 1 (4.2) 1 (4.2) 7 (29.2) 15 (62.5)
Metastases*** M0 337 (90.6) 15 (4.5) 101 (30.0) 138 (40.9) 83 (24.6) <0.001
M1 35 (9.4) 0 (0.0) 6 (17.1) 9 (25.7) 20 (57.1)
Margin status**** R0 356 (94.4) 15 (4.2) 105 (29.5) 145 (40.7) 91 (25.6) 0.004
R+ 21 (5.6) 0 (0.0) 3 (14.3) 6 (28.6) 12 (57.1)
Tumor subtype
Clear cell RCC 322 (81.7) 9 (2.8) 91 (28.3) 128 (39.8) 94 (29.2) 0.813
Papillary RCC 42 (10.7) 6 (14.3) 14 (33.3) 16 (38.1) 6 (14.3)
Chromophobe RCC 22 (5.6) 0 (0.0) 5 (22.7) 9 (40.9) 8 (36.4)
Oncocytoma 8 (2.0) 0 (0.0) 1 (12.5) 4 (50.0) 3 (37.5)
*Chi-square test using linear-by-linear association, significant P values <0.05 are given in bold. **157 cases were pNx or not assessed, pN+ includes all N-positive
cases. ***22 cases were Mx or not assessed. ****17 cases were Rx.
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Figure 1 Immunostaining of RECK in renal cell tissue. RECK expression was mainly seen in the tubuli and in the capillaries of the glomeruli
shown here in the medulla of non-malignant kidney tissue (A) and in the non-malignant renal cortex (B). RECK expression increased from clear
cell carcinoma (C) over papillary (D) and chromophobe (E) carcinoma to oncocytoma (F). Magnification: 200× (A, B), 400× (C-F).
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subtypes, several immunohistochemical markers have
been suggested, but until now, no biomarker is in
routine clinical use for prognostic purposes [5].
In search for new, more useful biomarkers to diagnose
RCC or to improve prognosis we aimed to determine
the (dys-)balance of an endogenous inhibitor of matrix
metalloproteinases (MMPs) and an inducer of MMPs,
namely reversion-inducing cysteine-rich protein with Kazal
motifs (RECK) and extracellular matrix metalloproteinase
inducer (EMMPRIN, CD147), which we have shown to be
responsible for a dysbalance in urothelial carcinoma of the
bladder [6]. Hitherto, nothing is known for RECK in kidney
cancer, but several studies exist indicating EMMPRIN as a
prognostic marker or overexpressed in RCC [7-10]. Here
we assessed RECK and EMMPRIN in Western blot
assays and in immunohistochemical staining in 395
matches (394 for EMMPRIN) of renal cell tumor tissue and
adjacent normal renal tissue on a tissue microarray (TMA)
and related them to each other and to clinicopathological
parameters of the patients.Methods
Patients
Tissue of 395 patients which had been radically or partially
nephrectomized at the Department of Urology, Charité
University Hospital between 1992 and 2004 was used for
the TMA study with the permission of the local ethics
committee (Ethikausschuss 1 Campus Charité – Mitte,
document no. EA1/134/12). Tumor stages were deter-
mined according to the latest version of the TNM classifi-
cation by the International Union against Cancer [11] and
tumor grades were reviewed by a single pathologist (A.E.)
according to the Fuhrman system. Clinicopathological
patient characteristics are listed in Table 1. The median age
was 60 years at nephrectomy (range 21–86), 257 (65.1%)
patients survived and 138 (34.9%) died within follow-up
times from 0 to 194 months (median 112 months). All
cases were selected according to availability of the tissue as
well as of follow-up data and were not stratified in any
way. Additional eight pairs of tissue with the above
mentioned conditions were used for Western blots,
but from nephrectomies of the years 2009 and 2010.
Figure 2 Immunostaining of EMMPRIN in renal cell tissue. EMMPRIN expression was detected in the tubuli of non-malignant renal tissue as
shown in the medulla (A) and in the cortex of the kidney (B). Clear cell (C) and papillary (D) carcinoma tissues are shown exemplary for tumor
staining. Magnification: 200× (A, B), 400× (C, D).
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Areas of renal cell tumors and adjacent normal tissue
were marked on 3 μm HE stained sections by a board
certified pathologist (G.K.). Three tumor and two
normal tissue cores per case (1.0 mm diameter) were
punched out of the tissue blocks according to marked
areas and embedded into a new paraffin block as
TMA with up to 37 cases per block. Punching was
done with a tissue arrayer (Beecher Instruments,
Woodland, CA, USA).
Immunohistochemistry
TMA sections of 2–3 μm were deparaffinized with
xylene, gradually hydrated and cooked in 0.01 M citrate
buffer for 5 minutes. EnVision + Dual Link System-HRP
(DAB+), Cat. No. K4065 (DAKO, Hamburg, Germany)
was used for the staining procedure. Endogenous perox-
idase activity and non-specific binding were blocked
with the Dual Endogenous Enzyme Block reagent
(DAKO) for 10 minutes at room temperature. Primary
antibody was incubated for 40 minutes at room
temperature using RECK rabbit monoclonal antibody
[6,12] 1:250 (clone D8C7, Cat. No. 3433, Cell Signaling
Technology Inc., Boston, MA, USA) or EMMPRIN rabbit
polyclonal antibody [6,13] 1:500 (Cat. No. 34–5600,
Invitrogen, Karlsruhe, Germany). Secondary antibodies
conjugated to horseradish peroxidase labelled polymer
(DAKO) were applied for 40 minutes at room temperature,
followed by staining with 3,3′-diaminobenzidine (DAB+)
substrate chromogen (DAKO) and counterstaining with
hematoxilin. The optimal concentration of primaryantibody had been determined in dilution series on
test sections of larger tissue areas. Positive and negative
controls guaranteed persistent quality of the immunostain-
ing. RECK and EMMPRIN staining were examined within
a range of negative (0) over weak (1) and moderate (2) to
strong (3) by a pathologist and a scientist who were
blinded for patient outcome as an average for spots of the
same case and morphology. Equivocal cases were discussed
at a double-headed microscope to reach consent.
Western blots
Western blots were performed as described before
[6]. Briefly, protein concentration of tissue lysates was
determined using the Pierce Microplate BCA Protein
Assay Kit (Pierce Biotechnology, Rockford, IL, USA).
Twenty μg of protein each were separated on a 7.5%
(RECK) or 10% (EMMPRIN) sodium dodecylsulfate poly-
acrylamide gel and transferred onto a polyvinylidene
difluoride membrane (Millipore Corp., Bedford, MA, USA).
Primary antibodies were the same as mentioned above
(immunohistochemistry) and used 1:1,000 (RECK) or
1:5,000 (EMMPRIN) for 1 h at room temperature. The
secondary antibody was horseradish peroxidase-conjugated
goat anti-rabbit immunoglobulin G (DAKO), diluted 1:2,000.
Enhanced chemiluminescence marked bands were detected
in a Fluor-S MultiImager (Bio-Rad Laboratories, Hercules,
CA, USA). After stripping, beta-actin controls were done as
follows: primary monoclonal mouse antibody to beta-actin
(Sigma-Aldrich, Munich, Germany) 1:50,000 and as second-
ary antibody horseradish peroxidase-conjugated rabbit anti-
mouse immunoglobulin G (DAKO), diluted 1:5,000.
Figure 3 RECK expression is tumor-specific. The average staining intensity for RECK decreased to 13% in tumor tissue compared to normal
tissue, whereas EMMPRIN staining remained unchanged (A). Mean RECK staining intensities for the tumor subtypes ± standard error of the mean
are shown in (B). In comparison to their normal counterparts, RECK values increased gradually from 6% in clear cell carcinomas (CC) over 38% in
papillary carcinomas (Pap.) and 45% in chromophobe carcinomas (Chrom.) to 96% in oncocytomas (Oncocyt.). P values are given above the pairs
of columns (A, B). RECK and EMMPRIN antibodies were checked in Western blots (C). RECK bands at 125 kDa and 90 kDa were detected in
protein lysates of 8 pairs of tumor and adjacent normal renal tissue (control: beta-actin). These samples were also used to show the panel of
EMMPRIN bands, in our blot migrating between 35 and 74 kDa (control: beta-actin).
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Calculations were performed using SPSS for Windows 19
(SPSS Inc., Chicago, IL, USA). Associations were deter-
mined in bivariate correlation according to Spearman and
in chi-square tests using linear-by-linear association. Dif-
ferences between tumor and adjacent normal tissue were
analyzed by the Wilcoxon signed rank test for paired data
and the power of discrimination between malignant
and non-malignant was calculated in logistic regres-
sion analysis. Overall survival analysis was done using
Kaplan-Meier analysis and the log-rank test. The tests
were two-sided, significance was defined as P < 0.05.
Results
Expression of RECK and EMMPRIN in renal cell carcinoma
RECK expression was assessed in 395 cases and
EMMPRIN expression in 394 cases of renal neoplasms
on the TMA. Clinicopathological data of the patients
are given in Table 1 combined with staining intensities of
the targets. RECK staining was found in tumor-surroundingnormal tissue in the medulla (Figure 1A) as well as in the
renal cortex (Figure 1B). Distal tubuli were stained
stronger than proximal tubuli, and in the glomeruli
only capillaries were stained. RECK expression in nor-
mal and tumor cells appeared mainly granularly in the
cytoplasm. Interestingly, the average staining intensity
increased from clear cell carcinomas over papillary and
chromophobe carcinomas to oncocytomas (Figure 1C-F)
as proved by linear-by-linear association in a chi-square
test (Table 1). This was the only significant associ-
ation for RECK to clinicopathological parameters.
EMMPRIN expression, however, was mainly membranous
(Figure 2) and did not discriminate tumor subtypes
(Table 1). It was also detected in both, the medulla
(Figure 2A) and cortex of the kidney (Figure 2B),
but with stronger staining in the proximal tubuli
than in the distal ones and absent staining in the
glomeruli. Positive and negative controls for immu-
nohistochemical staining are given in an additional figure
(Additional file 1).
Table 2 RECK and EMMPRIN staining in renal tumors
RECK staining score Tumor Adjacent normal EMMPRIN staining score Tumor Adjacent normal
Cases (%) Cases (%) Cases (%) Cases (%)
0 325 (82.3) 17 (4.5) 0 15 (3.8) 6 (1.7)
1 49 (12.4) 92 (24.5) 1 111 (28.2) 93 (25.7)
2 13 (3.3) 185 (49.2) 2 157 (39.8) 179 (49.4)
3 8 (2.0) 82 (21.8) 3 111 (28.2) 84 (23.2)
Total 395 (100) 376 (100) Total 394 (100) 362 (100)
Mean value 0.3 1.9 Mean value 1.9 1.9
Median 0.0 2.0 Median 2.0 2.0
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clinicopathological data
EMMPRIN expression in 394 renal neoplasms was
bivariately correlated to clinicopathological parameters
(listed in Table 1) according to Spearman, Spearman’s
rank correlation coefficient rs > 0.200 was considered
relevant. EMMPRIN correlated significantly (P < 0.001)Figure 4 EMMPRIN is a prognostic marker in renal cell
carcinoma. Kaplan-Meier analyses show RECK-positive (0) and RECK-
negative (1–3) staining intensities (A) or low EMMPRIN (0/1) and
high EMMPRIN (2/3) staining intensities (B) connected with overall
survival of the patients after nephrectomy. Oncocytomas were
excluded. Curves of all 387 cases (386 for EMMPRIN) are shown at
the left, curves of the selected 181 pN0/M0 cases only (180 for
EMMPRIN) are depicted at the right. High EMMPRIN expression was
significantly associated with a decrease in overall survival, even in
pN0/M0 cases only, while RECK did not discriminate subgroups.
Censored cases are marked (+).with pT staging (rs = 0.289) and with Fuhrman grading
(rs = 0.382). Associations of the data in chi-square
tests confirmed these interrelations (Table 1). More-
over, positive associations were found to lymph node
involvement (pN0 versus pN+, P = 0.003), metastasis
(M0 versus M1, P < 0.001) and margin status (R0 versus
R+, P = 0.004; Table 1).Tumor-specificity of RECK
Comparison of tumor and adjacent normal tissue pairs
revealed a significant decrease of RECK expression in
the tumor areas (Wilcoxon matched-pairs signed rank
test, P < 0.001), whereas expression of EMMPRIN remained
unchanged (P = 0.991, Figure 3A). A vast majority of 82% of
the carcinomas was assessed to be RECK-negative so that
further analyses concerning associations and survival
analyses failed to become significant. All staining
results for RECK and EMMPRIN are shown in Table 2.
Logistic regression was performed to further determine
the power of RECK to discriminate between tumor and
normal renal tissue. With an overall correct classification
value of 88.7% RECK discriminated the two groups very
well, which was also reflected in the receiver operating
curve analysis (curve not shown). The area under the
curve (AUC) was calculated as 0.925 with a confidence
interval from 0.904 to 0.945.
RECK staining intensity discriminated the tumor sub-
types as mentioned above, increasing gradually from clear
cell carcinoma to oncocytoma (see also Table 1), but with
constantly high levels in the normal tissue (Figure 3B). All
carcinoma subtypes, except for oncytoma, showed signifi-
cant differences in RECK expression between tumor and
matched normal tissues (Wilcoxon matched-pairs signed
rank test; P < 0.001 for clear cell and papillary carcinoma;
P = 0.002 for chromophobe carcinoma; P = 1.000 for
oncocytoma). Western blots also presented less amounts
of RECK in the tumor tissue (Figure 3C). Eight pairs of
renal cell carcinoma and adjacent normal tissue presented
the active glycosylated form of RECK migrating at
125 kDa [12] and a lower RECK band of about 90 kDa.
Table 3 Cox regression analyses of clinicopathological factors, RECK and EMMPRIN in 181 cases* of pN0/M0 renal
carcinoma
Variable Univariate analyses Multivariate analyses (RECK) Multivariate analyses (EMMPRIN)
Inclusion Backward** Inclusion Backward**
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Sex 0.764 0.361 0.766 0.405 0.745 0.356
Male / female (0.429-1.362) (0.409-1.434) (0.398-1.393)
Age 1.047 0.006 1.047 0.008 1.048 0.006 1.049 0.006 1.046 0.009
continous (1.013-1.081) (1.012-1.083) (1.013-1.083) (1.014-1.086) (1.011-1.082)
pT stage 2.800 <0.001 2.595 0.001 2.958 <0.001 2.521 0.002 2.581 0.002
pT1-2 / pT3-4 (1.628-4.817) (1.443-4.669) (1.690-5.175) (1.397-4.548) (1.434-4.643)
Fuhrman grade 1.569 0.242 1.467 0.365 1.130 0.779
G1-2 / G3-4 (0.738-3.333) (0.640-3.363) (0.481-2.656)
Surgical margin status*** 5.818 0.001 2.342 0.143 2.825 0.078 2.879 0.068
R negative / positive (2.006-16.879) (0.750-7.308) (0.891-8.953) (0.926-8.950)
RECK expression 1.063 0.880 1.040 0.930
negative / positive (0.479-2.358) (0.431-2.510)
EMMPRIN expression* 2.815 0.005 2.538 0.014 2.546 0.012
low (0,1) / high (2/3) (1.372-5.776) (1.208-5.333) (1.229-5.277)
*EMMPRIN expression in 180 cases: 153 clear cell, 17 papillary (18 for RECK), 10 chromophobe renal cell carcinomas. Oncocytomas were excluded due to
benignity. **Reduced model following backward Likelihood elimination (P = 0.05 for entry and P = 0.10 for removal). ***175 cases, 6 cases were Rx.
Abbreviations: HR Hazard ratio, CI Confidence interval, P P value.
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weight between about 74 kDa and 35 kDa which represent
differentially glycosylated forms of EMMPRIN.
Survival analysis with RECK and EMMPRIN
Univariate overall survival analysis according to Kaplan-
Meier confirmed the study cohort to be representative,
because the important tumor parameters pT stage,
Fuhrman grade, nodal status (pN), metastases before
surgery (M), and surgical margin status (R) significantly
differentiated low risk cases with an advantage in sur-
vival from high risk cases with shorter survival times
(P < 0.001 for all parameters). Oncocytomas (8 cases)
had been excluded from survival analyses to avoid a
possible bias due to benignity. Data were dichoto-
mized as mentioned above or as negative/positive
(pN, M, R). RECK expression in renal carcinoma did
not differentiate according to survival time, either in
the whole group of 387 cases or in the subgroup of
181 pN0/M0 cases (Figure 4A). EMMPRIN expression,
however, clearly discriminated cases with low EMMPRIN
expression and an advantage in survival (127 cases, 27
events) from cases with high EMMPRIN expression and
shorter survival times (259 cases, 109 events, P < 0.001,
Figure 4B left). The five-year survival rate decreased
accordingly from 87.4% to 75.9%. Using 180 cases of
pN0/M0 only, we obtained similar results with 62 cases of
low expression (9 events) and 118 cases of high expression(44 events, P = 0.003, Figure 4B right) and five-year sur-
vival rates of 91.9% and 79.5%, respectively. Kaplan-Meier
analyses for non-dichotomized EMMPRIN data show the
gradual decrease of survival time with increasing
EMMPRIN levels for all cases as well as for the pN0/M0
cases, but they should be considered with reservation due
to partially small subgroups (Additional file 2). Even for
the pN0/M0 cases multivariate analyses using the Cox
proportional hazards regression model emphasized
EMMPRIN as an independent predictor of survival
(Table 3). Univariate analyses of RECK, EMMPRIN and
the clinicopathological parameters sex, age, pT stage,
Fuhrman grade and surgical margin status R resulted in
the four significant factors age, pT, R and EMMPRIN,
which remained significant in the multivariate inclusion
model as well as in the backward likelihood calculation,
besides R (Table 3). RECK expression again remained
irrelevant for survival prognosis as already shown in
the Kaplan-Meier analyses. Even considering RECK in
adjacent normal renal tissue or in the difference
tumor/normal tissue, there was no relevant association.
All results were comparable if only the major subgroup of
clear cell RCC was selected.
Discussion
To our knowledge, nothing is known about the tumor
suppressor RECK in renal cell carcinoma. Due to our
findings of RECK/EMMPRIN imbalance in urothelial
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processes, we decided to look not only at RECK, but also
at the EMMPRIN counterpart in renal cell carcinoma.
RECK and EMMPRIN were mostly localized as expected.
RECK was found with cytoplasmic granular staining as
shown for prostate carcinoma [14], urothelial bladder
carcinoma [6] and colorectal carcinoma [15], although
membranous staining described for the other tumor
entities was not prominent. EMMPRIN, however, was
mainly localized at the plasma membrane, consistent
with our findings for urothelial bladder carcinoma [6]
and colorectal carcinoma [16] and consistent with
other studies, among them studies on human kidney
tissue [9,17] and RCC [7,8,10,18].
We did not find any difference in staining intensities
of EMMPRIN between tumor and adjacent normal
tissue. This is in contrast to previous studies on RCC
which presented low or undetectable levels of EMMPRIN
in normal renal epithelia [7,8,10,18], possibly due to the
use of antibodies with different epitopes. Nevertheless,
our findings are supported by Shimada et al. [17] who
detected EMMPRIN in tubular renal cells, but not in
glomeruli. Furthermore, our EMMPRIN antibody proved
to be specific, as shown in our Western blot experiments
and in the literature [13] so that we could not confirm the
diagnostic potential for EMMPRIN in kidney cancer
research. RECK, however, contains diagnostic potential as
we could demonstrate a strong decrease in RCC as
compared to adjacent normal tissue. This decrease was
more pronounced than in prostate carcinoma [14,19] and
fits also well to findings for colorectal cancer [15]
and other tumor entities (reviewed in [20,21]).
We found increasing RECK levels in different renal
neoplasms, from clear cell carcinoma over papillary to
chromophobe carcinoma and oncocytoma, in which
RECK expression became similar for tumor and normal
tissue. A possible explanation could be different points
of origin, because clear cell and papillary carcinoma
are supposed to originate from proximal tubules [22]
(but perhaps distal tubules, too [4]) and chromophobe
carcinoma and oncocytoma from intercalated cells of
the collecting duct [4,23]. Higher RECK levels could
also contribute to decreasing malignancy up to the
benign oncocytoma, but it would be considered as an
early marker for malignancy due to the high percentage of
RECK-negative tumors in our study.
Several studies on EMMPRIN in RCC indicate a positive
correlation with pT stage [7,8,10,18] and Fuhrman grade
[7,8,10,18]. Decreased survival rates were shown with
higher EMMPRIN levels in Kaplan-Meier analyses
[7,8,10,18]. We confirmed these EMMPRIN characteristics
for RCC in our work with a larger number of cases
(386 versus 52–100) and furthermore, we found
EMMPRIN as an independent predictive marker forpN0/M0 cases. Independence in prognosis was shown
before for up to 53 patients regarding EMMPRIN
alone in all stages of RCC [7,8,10,18] or in combination
with vascular endothelial growth factor in advanced RCC
[7,8,10,18]. Therefore, our study gives additional informa-
tion on the clinically interesting group of cases without evi-
dent progression which could benefit from a new marker
independent from clinicopathological characteristics.
Conclusions
In summary, we propose RECK as a diagnostic marker
for RCC and the subtypes of RCC suggesting that
RECK decrease is an early step in tumorigenesis, whereas
EMMPRIN as a prognostic marker is a later event associated
with increasing aggressiveness.
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